Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Due to the high prevalence of non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis B virus (HBV) infection, a significant proportion of patients suffer from both conditions simultaneously. The management of NAFLD in patients with concurrent HBV infection presents unique challenges, primarily due to the complex interplay between these two diseases. Nanomaterials have gained widespread attention due to their ability to overcome the limitations of conventional therapies. This review provides an overview of the current advances in therapeutic nanomaterials for NAFLD and explores their potential applications for personalized and effective management in patients with concurrent HBV infection. Furthermore, we discuss the challenges and future directions in the development of nanomaterials for the treatment of coexisting liver diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954402 | PMC |
| http://dx.doi.org/10.2147/IJN.S510271 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biejia-Ruangan enhances the efficacy of entecavir in reversing liver cirrhosis in patients with chronic HBV infection: A seven-year open-label follow-up cohort study.
J Ethnopharmacol
September 2025
Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015, China. Electronic address:
Ethnopharmacological Relevance: Biejia-Ruangan (BRG) has been approved in China as an antifibrotic traditional Chinese medicine for patients with chronic liver diseases; however, data on the reversal of hepatitis B-related cirrhosis by BRG are still limited.
Aim Of The Study: To investigate the reversal effect of BRG in patients with hepatitis B-related cirrhosis.
Materials And Methods: Hepatitis B-related cirrhotic patients who received either entecavir (ETV) monotherapy or combination therapy with ETV and BRG for 7 years, were analysed.
Interferon-induced miR-7705 modulates the anti-virus activity of cholesterol 25-hydroxylase.
J Virol
September 2025
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin, China.
Unlabelled: Cholesterol 25-hydroxylase (CH25H), an interferon-stimulated gene (ISG), has been implicated in broad-spectrum antiviral immunity. Here, we identify CH25H as a potent suppressor of hepatitis B virus (HBV) replication that significantly outperforms IFN-α in reducing HBV DNA, pregenomic RNA (pgRNA), HBsAg, and HBeAg, without inducing cytotoxicity. However, CH25H is weakly expressed in hepatocytes and only modestly induced by type I interferon.
View Article and Find Full Text PDFA Prospective Cohort Study of Hepatitis B Virus Vaccination in Pediatric Heart Transplant Recipients: Cellular and Humoral Immune Responses and the Role of Innate Immunity.
Pediatr Infect Dis J
September 2025
From the Pediatric Infectious Diseases Unit, Gregorio Marañón University Hospital, Madrid, Spain.
Background: Vaccination is a key strategy to reduce infectious disease mortality. In pediatric heart transplant recipients (HTRs), the use of immunosuppressive therapy weakens immune responses, increasing the risk of viral infections. This study aimed to evaluate the immunogenicity of hepatitis B virus (HBV) revaccination in this vulnerable population.
View Article and Find Full Text PDFClinical burden of HDV in Spain: Incidence, prevalence, and associated comorbidities.
JHEP Rep
October 2025
HEOR-Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.
Background & Aims: HDV leads to the most severe form of viral hepatitis. It has been estimated to affect 5-13% of people who have chronic HBV worldwide. Evidence of HDV incidence, prevalence, and disease burden in Spain is limited.
View Article and Find Full Text PDFType 1 regulatory cells suppress T-cell cytotoxicity to alleviate liver injury during acute hepatitis B virus infection in mice.
J Immunol
September 2025
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Hepatitis B virus (HBV) exclusively infects hepatocytes and produces large quantities of subviral particles containing its surface antigen (HBsAg). T cells play a central role in controlling HBV infection but can also mediate liver injury and contribute to disease progression. However, the mechanisms that regulate T-cell responses to eliminate the virus without causing immunopathology during acute HBV infection remain poorly defined.
View Article and Find Full Text PDF